Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Recurrence 1Ovarian Neoplasms 1

Interventions

pembrolizumab 524Specimen Handling 383Carboplatin 377Magnetic Resonance Spectroscopy 336Cisplatin 332Nivolumab 308Cyclophosphamide 298Radiotherapy 257Paclitaxel 255Gemcitabine 235Biopsy 235Bevacizumab 218Dexamethasone 169durvalumab 168Oxaliplatin 163Capecitabine 158Rituximab 157Fluorouracil 149venetoclax 147Docetaxel 147Etoposide 142Drug Therapy 142atezolizumab 141Doxorubicin 134Ipilimumab 129Radiosurgery 120Prednisone 120Lenalidomide 119Leucovorin 113fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × CYH33 × 1 year × Clear all
NCT05043922 2026-01-30

A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

Haihe Biopharma Co., Ltd.

Phase 2 Active not recruiting
93 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡